Aktuellt
SENASTE
Redeye provides an update in relation to Optomed’s Q3 2023 report. The report came in better than expected, with sales of EUR4.2m (EUR3.7m) and a solid positive cash flow from operating activities. Furthermore, we assume that the additional data has not been sent in yet to the FDA. We now expect a potential FDA approval in early 2024 and view this as a major trigger for the share. Moreover, we only make minor estimate changes; however, we increase our WACC, which renders in an updated fair value range, including a new base case of EUR7.5 (8).
LÄS MER
